MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study)

International Journal of Molecular Sciences

Olga Kałużyńska¹  Justyna Szyburska¹  Dominik Strzelecki¹  Adam Wysokiński² 

[1] Department of Affective and Psychotic Disorders, Medical University of Łódź, Central Clinical Hospital, Czechosłowacka 8/10, 92-216 Łódź, Poland;Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Łódź, Central Clinical Hospital, Czechosłowacka 8/10, 92-216 Łódź, Poland;

关键词: matrix metallopeptidase-9 (MMP-9);    sarcosine;    NMDA (N-methyl-;    ">d-aspartate) receptor;    glutamatergic system;    schizophrenia;    negative symptoms;   

DOI  :  10.3390/ijms17071075

来源: DOAJ

【 摘 要 】

Aim: Find changes in matrix metallopeptidase-9 (MMP-9) levels during augmentation of antipsychotic treatment with sarcosine and a relationship between schizophrenia symptoms severity and initial level of MMP-9. Method: Fifty-eight patients with diagnosis of schizophrenia with predominant negative symptoms participated in a six-month prospective RCT (randomized controlled trial). The patients received two grams of sarcosine (n = 28) or placebo (n = 30) daily. At the beginning, after six weeks and after six months MMP-9 levels were measured. Severity of symptomatology was assessed with the Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS). Results: MMP-9 serum levels were stable after six weeks and six months in both groups. We noted improvement in negative symptoms, general psychopathology and total PANSS score in sarcosine group compared to placebo; however, there was no correlations between serum MMP-9 concentrations and PANSS scores in all assessments. Initial serum MMP-9 concentrations cannot be used as an improvement predictor acquired during sarcosine augmentation. Conclusions: Our results indicate that either MMP-9 is not involved in the N-methyl-d-aspartate (NMDA)-dependent mechanism of sarcosine action in terms of clinical parameters or sarcosine induced changes in peripheral MMP-9 concentrations cannot be detected in blood assessments.

【 授权许可】

Unknown